神经内分泌肿瘤治疗市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

神经内分泌肿瘤治疗市场按产品(生长抑素类似物 (SSA)、靶向治疗、化疗等)、适应症、最终用户和地理位置细分

市场快照

Neuroendocrine Tumor Treatment Market Size
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 10 %
Neuroendocrine Tumor Treatment Market Major Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

由于神经内分泌癌患病率的增加、技术进步和政府举措数量的增加,神经内分泌肿瘤治疗市场将呈现快速增长。

根据美国临床肿瘤学会 (ASCO) 的数据,神经内分泌肿瘤的患病率在全球范围内呈上升趋势,尽管这是一种罕见的疾病,因为据估计,在美国每年有超过 12,000 人受到神经内分泌肿瘤的影响。美国。因此,神经内分泌肿瘤的日益流行有助于提高治疗这种罕见疾病的药物的采用率。

与预计在预测期内阻碍神经内分泌肿瘤市场增长的其他药物相比,这些孤儿药的开发成本要高得多。各种国际组织的政府举措和资金也显着增加,预计将在不久的将来推动整个市场。

报告范围

根据报告的范围,神经内分泌肿瘤是一种罕见的肿瘤,起源于特殊的身体细胞,称为神经内分泌细胞,被称为神经内分泌肿瘤。神经内分泌肿瘤起源于产生激素的细胞,因此,它产生激素并将激素释放到血液中,以响应从神经系统接收到的信号。它可以发生在身体的任何部位,但最常见于胰腺、消化道、肺、直肠和阑尾。神经内分泌肿瘤可以是良性的(非癌性的)或恶性的(癌性的)。

By Products
Somatostatin Analogs (SSAs)
Targeted Therapy
Chemotherapy
Others
By Indication
Lungs
Pancreas
Gastrointestinal
Others
By End User
Hospitals
Clinics
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

主要市场趋势

生长抑素类似物预计将在预测期内主导神经内分泌肿瘤治疗市场

生长抑素类似物 (SSAs) 被发现是广泛用于治疗神经内分泌癌的药物,因为它们控制癌症的生长、症状和靶向生物标志物。由于 SSA 提供的安全治疗程序,它们占最大的收入份额。

发现 SSA 通常用于治疗对放射治疗和手术有抵抗力的患者。因此,许多 SSA 目前正处于临床试验阶段并等待批准,因此预计市场将在预测期内出现高速增长。

Neuroendocrine Tumor Treatment Market Share

北美有望主导神经内分泌肿瘤治疗市场

由于神经内分泌疾病发病率的上升、发达的医疗保健基础设施、强大的临床管道、人们的高度认识以及主要市场参与者的存在,北美在神经内分泌肿瘤市场上占据主导地位。该地区还有促进神经内分泌治疗的支持性保险政策,例如医疗保险、医疗补助和 Tricare,有助于推动市场的整体增长。

由于该地区神经内分泌肿瘤的发病率上升,预计亚太市场也将出现显着增长。

Neuroendocrine Tumor Treatment Market Growth

竞争格局

主要参与者采取了产品发布、区域扩张、合作伙伴和分销协议等战略,以加强其市场地位。还发现有各种公司专注于有机增长战略产品批准和其他,如专利和活动。市场上见证的无机增长战略活动是收购、合作与合作。

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Neuroendocrine Carcinoma

      2. 4.2.2 Technological Advancements

      3. 4.2.3 Rising Number of Government Initiatives

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of Development

      2. 4.3.2 Lack of Awareness Among People

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Products

      1. 5.1.1 Somatostatin Analogs (SSAs)

      2. 5.1.2 Targeted Therapy

      3. 5.1.3 Chemotherapy

      4. 5.1.4 Others

    2. 5.2 By Indication

      1. 5.2.1 Lungs

      2. 5.2.2 Pancreas

      3. 5.2.3 Gastrointestinal

      4. 5.2.4 Others

    3. 5.3 By End User

      1. 5.3.1 Hospitals

      2. 5.3.2 Clinics

      3. 5.3.3 Others

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Boehringer Ingelheim International GmbH

      2. 6.1.2 Bristol-Myers Squibb

      3. 6.1.3 Eli Lilly & Company

      4. 6.1.4 F. Hoffmann-La Roche Ltd.

      5. 6.1.5 Ipsen

      6. 6.1.6 Novartis AG

      7. 6.1.7 Pfizer Inc.

      8. 6.1.8 Progenics Pharmaceuticals

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Neuroendocrine Tumor Treatment Market market is studied from 2018 - 2026.

The Neuroendocrine Tumor Treatment Market is growing at a CAGR of 10% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Pfizer Inc., Novartis AG, Ipsen, Boehringer Ingelheim International GmbH, Eli Lilly & Company are the major companies operating in Neuroendocrine Tumor Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!